Single- and multiple-ascending dose study of ABT 288 in younger volunteers

Trial Profile

Single- and multiple-ascending dose study of ABT 288 in younger volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2013

At a glance

  • Drugs ABT 288 (Primary)
  • Indications Alzheimer's disease; Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 08 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top